127 7 DELIRIUM | PART THREE Results Between January 1, 2011 and June 15, 2016, a total 100 patients were randomly assigned: 50 patients per treatment arm (Figure 1). Data were missing from one patient in each treatment arm. Ninety-eight patients (49 patients per treatment arm) were included in the ITT cohort; 81 patients (40 in the olanzapine arm, and 41 in the haloperidol arm) in the PP cohort. Figure 1. CONSORT diagram. Randomised (n= 100) 50 allocated to olanzapine 49 received at least one dose of allocated intervention* 9 discontinued treatment 6 due to death 3 due to non-compliance 50 allocated to haloperidol 49 received at least one dose of allocated intervention* 8 discontinued treatment 7 due to death 1 due to non-compliance Analyzed Intention-to-treat n= 49 Per protocol n = 40 Analyzed Intention-to-treat n= 49 Per protocol n= 41 *Data were missing from one patient in each treatment arm Table 1 describes the baseline characteristics of the ITT population, which were generally well balanced between the two arms. The majority of the patients was male (69.4%) with a mean age of ±69 years in both treatment groups. Mean DRS-R-98 total score at randomization was approximately 23 in both arms. Median number of precipitating factors for delirium was 2 (Interquartile Range [IQR], 1-3; range, 0-5). Most patients (n= 89; 91%) were admitted to a hospital ward. Reason for hospitalization was an emergency admission in 84.7% of the patients.
RkJQdWJsaXNoZXIy MjY0ODMw